Jump to content

MYCO-004

From Wikipedia, the free encyclopedia
MYCO-004
Clinical data
Other namesMYCO004
Routes of
administration
Transdermal (patch)[1]
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

MYCO-004 is a patch-delivered psychedelic tryptamine which is under development for the treatment of psychiatric disorders.[2][3][1] It is anticipated to allow for precision dosing and to have a short duration of approximately 2 hours.[4] The drug is being developed by Mydecine.[2][3] As of December 2021, it is in preclinical research for psychiatric disorders.[2][3] The exact chemical structure of MYCO-004 does not yet seem to have been disclosed.[2]

See also

[edit]

References

[edit]
  1. ^ a b Psychedelic Alpha (10 January 2022). "Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds". Psychedelic Alpha. Retrieved 29 January 2025. The Company's AI program has already led to identifying promising enhancements to psilocybin and psilocin which they have included in their recent patent application around MYCO-004, which directly addresses further precision in delivery control and shelf stabilization through a dermal route of administration.
  2. ^ a b c d "MYCO 004". AdisInsight. 15 December 2021. Retrieved 29 January 2025.
  3. ^ a b c "Delving into the Latest Updates on MYCO-004 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
  4. ^ Psychedelic Alpha (24 June 2021). "Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004". Psychedelic Alpha. Retrieved 29 January 2025.